Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Read More: Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discoveryVariational AI introduces Enki™ 4: an improved algorithm and architecture designed to scale, expanding the pre-trained target coverage from 592 to 760 and now applicable to proximity-based therapeutics and novel payloads for antibody drug conjugates. Read More about Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Our Latest News
Featured
Blog & Press
3C Therapeutics and Variational AI Launch Generative AI Collaboration to Design Next-Generation Degrader Antibody Conjugates, Supported by Innovate BC
Vancouver-based 3C Therapeutics to apply Variational AI’s Enki™ platform to ligand design for proprietary TriCore DAC platform under Innovate BC’s Integrated Marketplace program Read More about 3C Therapeutics and Variational AI Launch Generative AI Collaboration to Design Next-Generation Degrader Antibody Conjugates, Supported by Innovate BC
Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Variational AI introduces Enki™ 4: an improved algorithm and architecture designed to scale, expanding the pre-trained target coverage from 592 to 760 and now applicable to proximity-based therapeutics and novel… Read More about Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Enamine joins Variational AI in Agora Open-Science PRMT6 Discovery Effort
Variational AI is pleased to share that Enamine has joined the Agora Open Science Trust collaboration focused on discovering novel PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA), a… Read More about Enamine joins Variational AI in Agora Open-Science PRMT6 Discovery Effort
Variational AI and Rakovina Therapeutics Expand Collaboration to Accelerate Next-Generation ATR Inhibitors
Variational AI and Rakovina Therapeutics expand their collaboration to advance Rakovina’s kt-5000 series of ATR inhibitors Read More about Variational AI and Rakovina Therapeutics Expand Collaboration to Accelerate Next-Generation ATR Inhibitors
Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Building on their initial hit series, Variational AI and Rakovina Therapeutics share promising new results on ATR inhibitors generated with Enki. The latest findings reveal compounds that balance potency, selectivity,… Read More about Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI, a generative AI drug discovery company, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki™ platform to… Read More about Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Upcoming Events
SeoulVariational AI at BIX 2026 in Seoul
Variational AI will be at BIOPLUS-INTERPHEX KOREA 2026 in Seoul from October 28, where Canada is the Country of Honour. Handol Kim and Valentin Beuchillot will attend.
VancouverVariational AI at Invest in BC 2026
Variational AI will attend the 11th annual Invest in BC conference in Vancouver on November 3, part of Life Sciences BC’s Life Sciences Investment Week.
CologneVariational AI at BIO-Europe 2026
Variational AI will participate in BIO-Europe 2026, one of the world’s leading partnering conferences for the biotechnology and pharmaceutical industries. The event brings together biotech companies, pharmaceutical firms, investors, and technology innovators from across the global life sciences ecosystem to explore partnerships, licensing opportunities, and new approaches to advancing therapeutic development. Meet the Variational AI…
Media & Resources
Variational AI featured in AWS’s “Canada’s AI Innovators” series
Variational AI is one of nine companies featured in AWS’s Canada’s AI Innovators series, recognising how our Enki™ generative AI platform is making small molecule drug discovery 100x more efficient. Read More about Variational AI featured in AWS’s “Canada’s AI Innovators” series
AI, Drug Discovery & Startups: A Candid Talk with Handol Kim, CEO of Variational AI
In this conversation, Handol shares how his team is rethinking drug discovery using generative AI, tackling one of the most complex and high-stakes challenges in science. From a 25-year career… Read More about AI, Drug Discovery & Startups: A Candid Talk with Handol Kim, CEO of Variational AI
How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)
From Handshake to Breakthrough: How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording) In this 60-minute fireside chat, Rakovina Therapeutics and Variational AI share the story behind… Read More about How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)
What’s with RWE Podcast: Generative AI for Drug Discovery
Handol Kim, CEO of Variational AI, shares insights on the growing role of generative AI in pharmaceutical research. The discussion highlights how advanced machine learning approaches can help researchers explore… Read More about What’s with RWE Podcast: Generative AI for Drug Discovery